In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent <sup>18</sup>F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The gene discussed is CXCR4; the disease is neuroendocrine carcinoma.